SCYNEXIS Inc (NAS:SCYX)

$ 1.34 -0.06 (-4.29%) Market Cap: 50.73 Mil Enterprise Value: -4.50 Mil PE Ratio: 0 PB Ratio: 0.88 GF Score: 51/100

SCYNEXIS Inc Annual Shareholders Meeting Transcript
Jun 14, 2023
Q3 2022 SCYNEXIS Inc Earnings Call Transcript
Nov 09, 2022

$1.8 (-19.64%)

Earnings
SCYNEXIS Inc Corporate, Commercial and R&D Strategy Update Call Transcript
Oct 20, 2022
Q2 2022 SCYNEXIS Inc Earnings Call Transcript
Aug 15, 2022

$2.93 (+2.09%)

Earnings
Q1 2022 SCYNEXIS Inc Earnings Call Transcript
May 12, 2022

$1.87

Earnings
Q4 2021 SCYNEXIS Inc Earnings Call Transcript
Mar 29, 2022

$4.09 (-12.98%)

Earnings
SCYNEXIS Inc Corporate Update Call Transcript
Feb 10, 2022
SCYNEXIS Inc Hospital Pipeline Update and KOL Event - Call Transcript
Dec 06, 2021
Q3 2021 SCYNEXIS Inc Earnings Call Transcript
Nov 10, 2021

$5.67 (+1.25%)

Earnings
SCYNEXIS Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
SCYNEXIS Inc Corporate Commercial Launch Update Corporate Call Transcript
Jun 29, 2021
SCYNEXIS Inc Announces FDA Approval of Brexafemme As The First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections Corporate Call Transcript
Jun 02, 2021
SCYNEXIS, Inc. - Special Call Transcript
Mar 02, 2021
SCYNEXIS Inc Dr. Marco Taglietti Discusses SCYNEXIS Transcript
Aug 19, 2020
SCYNEXIS Inc Annual Shareholders Meeting Transcript
Jul 02, 2020
SCYNEXIS, Inc. - Special Call Transcript
Apr 21, 2020
SCYNEXIS Inc at Needham Healthcare Conference Transcript
Apr 14, 2020
SCYNEXIS, Inc. - Special Call Transcript
Jan 08, 2020
SCYNEXIS Inc to Discuss the Ibrexafungerp Data Presented at ECCMID 2019 - Conference Call Transcript
Apr 15, 2019

SCYNEXIS Inc Hospital Pipeline Update and KOL Event - Call Transcript

Dec 06, 2021 / 03:00PM GMT

Release Date Price: $6.65 (+4.23%)

Transcript

Operator

Good morning, and welcome to the SCYNEXIS Hospital Update Call. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the SCYNEXIS website following the conclusion of the event.

I would now like to turn the call over to Debbie Etchison of SCYNEXIS. You may begin.

Debbie Etchison

Hello, everyone, and welcome to today's conference call to discuss our hospital pipeline.

Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, leadership's expectations for our clinical results, future financial and operational performance as well as our business strategy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

Please refer to our filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.